Loading…
Eikon Therapeutics, Inc. is projected to decline to $9.18 by 2027, a 0% move from its current price of $9.21. EIKN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $8.82 | $9.22 | $9.64 | +0.09% |
| Aug 4 | $8.66 | $9.23 | $9.83 | +0.18% |
| Aug 5 | $8.55 | $9.23 | $9.98 | +0.26% |
| Aug 6 | $8.45 | $9.24 | $10.10 | +0.35% |
| Aug 7 | $8.37 | $9.25 | $10.22 | +0.44% |
| Aug 8 | $8.30 | $9.26 | $10.33 | +0.53% |
| Aug 9 | $8.24 | $9.27 | $10.43 | +0.62% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.24 | $9.27 | $10.43 | +0.62% |
| Week 2 | $7.89 | $9.32 | $11.02 | +1.24% |
| Week 3 | $7.65 | $9.38 | $11.51 | +1.86% |
| Week 4 | $7.46 | $9.44 | $11.95 | +2.49% |
| Week 5 | $7.30 | $9.50 | $12.36 | +3.12% |
| Week 6 | $7.16 | $9.56 | $12.76 | +3.75% |
| Week 7 | $7.04 | $9.61 | $13.13 | +4.39% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company based in the United States that develops medicines to address serious unmet medical needs.
Its product lineup includes EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers, with EIK1004 brain-penetrant to address brain metastases and primary brain malignancies; EIK1005, a WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor.
The company was incorporated in 2019 and is based in Millbrae, California.
Eikon Therapeutics, Inc. operates in the Healthcare sector and trades under the symbol EIKN.
The current price is $9.01. Its market cap is $487.79M and it ranks 3050.
The longer-term price outlook is bullish, with an average price of $13.29 by 2030 and $33.86 by 2050, and a maximum forecast of $24.88 by 2030 and $77.88 by 2050.
A major floor 32.3% below — a decisive break under it would weaken the trend.
The nearest floor, 3.4% below — buyers have tended to step in here.
The nearest ceiling, 41.7% above — a clean break opens room to run.
A major ceiling 57.8% above — clearing it would confirm fresh momentum.
Key EIKN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EIKN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.44 | Sell | $9.38 | Sell |
| MA 10 | $9.49 | Sell | $9.55 | Sell |
| MA 20 | $10.06 | Sell | $9.85 | Sell |
| MA 50 | $10.11 | Sell | $10.22 | Sell |
| MA 100 | $10.43 | Sell | $10.89 | Sell |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.36 | Neutral |
| Stoch RSI (14) | 62.63 | Neutral |
| CCI (20) | -89.51 | Neutral |
| Williams %R (14) | -75.97 | Info |
| MACD (12,26,9) | -0.09 | Sell |
| ROC (12) | -6.40 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 24.03 | Neutral |
| TRIX (15) | -0.30 | Sell |
| Awesome (5,34) | -0.80 | Sell |
| Ultimate (7,14,28) | 43.20 | Neutral |
| Momentum (10) | -0.56 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 9.29 | Sell |
| ADX (14) | 13.49 | Neutral |
| ATR (14) | 0.44 | Info |
The 30-day technical picture is bearish, with RSI14 at 40 and the 50-day simple moving average at $10.19.
Near-term support sits at $8.90 and resistance at $13.05, while the 30-day price range runs from $6.73 to $12.06.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.36 | $9.21 | $13.21 | 0% | Neutral | |
| $6.36 | $9.18 | $14.38 | 0% | Neutral | |
| $7.25 | $11.36 | $19.20 | +23% | Bullish | |
| $7.95 | $13.37 | $23.94 | +45% | Bullish | |
| $7.97 | $14.31 | $26.85 | +55% | Bullish | |
| $7.04 | $13.46 | $26.29 | +46% | Bullish | |
| $6.02 | $12.22 | $24.73 | +33% | Bullish | |
| $6.41 | $13.82 | $28.86 | +50% | Bullish | |
| $6.32 | $14.05 | $30.19 | +53% | Bullish | |
| $7.42 | $16.48 | $36.34 | +79% | Bullish | |
| $7.79 | $17.32 | $39.83 | +88% | Bullish | |
| $17.25 | $38.34 | $88.19 | +316% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $8.36 | $9.21 | $11.50 | +0.00% |
| September 2026 | $7.89 | $9.75 | $12.67 | +5.89% |
| October 2026 | $7.94 | $9.98 | $13.28 | +2.30% |
| November 2026 | $7.48 | $9.54 | $12.95 | -4.35% |
| December 2026 | $7.40 | $9.57 | $13.21 | +0.26% |
Click any year to see its month-by-month EIKN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, EIKN could reach as high as $13.21, with a base case around $9.21 and support toward $8.36 — roughly 0% from $9.21. Price action looks broadly range-bound.
Expect EIKN to range from $6.36 to $14.38 through 2027. The $9.18 average target implies a 0% move from current prices. That is 0% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The EIKN price prediction for 2028 points to an average of $11.36 (low $7.25, high $19.20) — a potential gain of +23% on today's $9.21. Momentum favours further upside here.
In 2029, EIKN is projected to trade between $7.95 and $23.94, averaging $13.37 — a potential gain of +45% from today's $9.21. That is up +18% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Eikon Therapeutics, Inc.'s 2030 outlook centres on $14.31, within a $7.97 to $26.85 range. That is up +7% on the projected 2029 average. That marks a +55% change versus current levels. Momentum favours further upside here.
By 2031, EIKN could reach as high as $26.29, with a base case around $13.46 and support toward $7.04 — roughly +46% from $9.21. Buyers look set to stay in control over this stretch.
Expect EIKN to range from $6.02 to $24.73 through 2032. The $12.22 average target implies a +33% move from current prices. That is -9% versus the projected 2031 average. Momentum favours further upside here.
The EIKN price prediction for 2033 points to an average of $13.82 (low $6.41, high $28.86) — a potential gain of +50% on today's $9.21. Buyers look set to stay in control over this stretch.
In 2034, EIKN is projected to trade between $6.32 and $30.19, averaging $14.05 — a potential gain of +53% from today's $9.21. That is up +2% on the projected 2033 average. Momentum favours further upside here.
Eikon Therapeutics, Inc.'s 2035 outlook centres on $16.48, within a $7.42 to $36.34 range. That is up +17% on the projected 2034 average. That marks a +79% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, EIKN could reach as high as $39.83, with a base case around $17.32 and support toward $7.79 — roughly +88% from $9.21. Momentum favours further upside here.
Expect EIKN to range from $17.25 to $88.19 through 2050. The $38.34 average target implies a +316% move from current prices. That is up +121% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in EIKN today (≈ 108.577633 EIKN) could be worth
$4,163.17
+$3,163.17 (+316%) by 2050 · US Dollar
Based on the average projected EIKN price of $38.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EIKNwould be worth at today's price.
$1,000 invested in EIKN on Feb 5, 2026 (≈ 66.666667 EIKN) would be worth
$614
-$386 (-38.6%) today · 0.61× · US Dollar
Based on a EIKN entry price of $15 vs. today's $9.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.9 | $1,034.83 | +3.5% |
| 1 month ago | $12.25 | $751.84 | -24.8% |
| 3 months ago | $9.68 | $951.45 | -4.9% |
| All time ago | $15 | $614 | -38.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EIKN forecast.
Our base-case forecast reaches $18.00 around 2050.
Implied market cap at $18.00: $974.5M
From 2026 to 2028 the forecast shows neutral sentiment, with 2026 avg $9.01 (ROI 0%), 2027 avg $8.73 (ROI -3.1%), and 2028 avg $10.45 (ROI 16%).
From 2029 to 2032 the outlook turns bullish, with 2029 avg $12.42 (ROI 37.8%), 2030 avg $13.29 (ROI 47.5%), 2031 avg $12.47 (ROI 38.4%), and 2032 avg $11.36 (ROI 26.1%).
From 2033 to 2035 the forecast remains bullish, with 2033 avg $12.60 (ROI 39.9%), 2034 avg $12.45 (ROI 38.2%), and 2035 avg $14.62 (ROI 62.3%).
The path extends into 2040 and 2050, with 2040 avg $15.18 (ROI 68.5%) and 2050 avg $33.86 (ROI 275.8%), indicating substantial long-run upside, though these are estimates and carry uncertainty.
Tap a question to reveal the answer.
Avg $13.29; min $7.43; max $24.88; ROI 47.5%; sentiment BULLISH.
Long-term outlook is bullish (2030 avg $13.29; 2050 avg $33.86; ROI up to 275.8%), though near-term years show ROI of 0% in 2026 and -3.1% in 2027, so results are not guaranteed.
The 2050 max is $77.88, so a $50 price is within the forecast, though it is not guaranteed.
Current price is $9.01 and market cap is $487.79M.
Bearish sentiment with RSI14 at 40; SMA50 at $10.19. Near-term support is $8.90 and resistance is $13.05, with a 30-day range from $6.73 to $12.06.
Eikon Therapeutics, Inc. Community Discussion
0Share your Eikon Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.